Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 10, 1998

View Archived Issues

MedImmune: Q3 1998 highlights

Aquila Biopharmaceuticals: Q3 1998 highlights

Sepracor: Q3 1998 highlights

MitoKor and Pfizer to collaborate on mitochondrial targets for neurodegenerative diseases

Two major clinical studies demonstrate chemo- and radioprotective activity of amifostine

FAME study will evaluate effects of lipid lowering in the elderly

Sangamo enters agreement with Zeneca for identification of novel gene targets

BMS to acquire Korean company

Promising interim results announced for SU-5416 phase I trial

WAY-135433 increases HDL cholesterol, protects against atherosclerosis and heart disease

Novel compounds from ADIR acting on the dopaminergic system

Compounds acting on metabotropic glutamate receptors disclosed by Lilly

Noncytotoxic thiocolchicine derivatives useful as muscle relaxants

Canadian team describes cardioprotective activity of AAA-135

New series from Agouron with inhibitory activity against MMPs and TNF-alpha production

Pharmacia & Upjohn patents new agents for CNS and neurodegenerative disorders

Specific MC4 receptor agonist reduces food intake in leptin-deficient and -resistant mice

LY-203638 has potent profibrinolytic effects in canine model of thrombosis

Pfizer presents preclinical profile of potent, full 5-HT1D receptor antagonist

RPR-118723: a novel anticonvulsant and potent glycine-site NMDA receptor antagonist

Knoll's promising new treatment for RA covered in depth at rheumatology congress

Reversible mixed MAO-A/MAO-B inhibitor discovered at Synthelabo is presented this week

Novel sodium channel blocker from Roche evaluated in vitro for neuroprotective efficacy

NK1 antagonist L-732138 exhibits activity indicating efficacy in neuropathic pain

Cevimeline improves symptoms of xerostomia in animal models, patients with Sjogren's syndrome

LEF-553: a potent mu-opioid receptor agonist with peripheral analgesic effects

Preclinical pharmacokinetics of MEN-11420 determined in rats; compound advances to clinical trials

Ciba Vision launches Vitravene in the U.S.

Knoll develops potential new antipsychotic agent with advantages over available therapies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...